The effect of symbiotic supplementation on the stress, anxiety and depression

The effect of symbiotic supplementation on the stress, anxiety and depression among overweight and obese adults

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180201038585N3

Enrollment

Registered

2019-01-12

Start date

2019-01-09

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overweight and obese. Overweight and obesity

Interventions

Intervention 1: Intervention group: Intervention group: En Interventions 1: 500mg capsules of synbiotic 1 per day for 8 weeks Interventions ,, Half an hour after lunch, the product of Biostimiran Comp

Eligibility

Sex/Gender

All

Age

18 Years to 49 Years

Inclusion criteria

Inclusion criteria: age between 18-49 willingness to participating in study BMI>25

Exclusion criteria

Exclusion criteria: Severe stress, depression and anxiety Pregnancy, lactation, menopause Drug addict, smoking and alcohol consumption Chronic diseases and inflammation Taking unti-depression, anxiety and stress drug Adherence to special diet

Design outcomes

Primary

Measure	Time frame
Anxiety. Timepoint: at baseline and after 8-weeks intervention. Method of measurement: DASS 21 questionnaire.;Stress. Timepoint: at baseline and after 8-weeks intervention. Method of measurement: DASS 21 questionnaire.;Depression. Timepoint: at baseline and after 8-weeks intervention. Method of measurement: DASS 21 questionnaire.	—

Secondary

Measure	Time frame
Weight. Timepoint: at baseline and after 8 weeks intervention. Method of measurement: digital scale.;Waist circumstance. Timepoint: at baseline and after 8 weeks intervention. Method of measurement: measuring tape.;BMI. Timepoint: at baseline and after 8 weeks intervention. Method of measurement: Formula.;Blood pressure. Timepoint: at baseline and after 8 weeks intervention. Method of measurement: sphygmomonometer.;Fasting blood sugar. Timepoint: at baseline and after 8 weeks intervention. Method of measurement: lab kit.;Triglyceride. Timepoint: at baseline and after 8 weeks intervention. Method of measurement: lab kit.;Cholesterol. Timepoint: at baseline and after 8 weeks intervention. Method of measurement: lab kit.;LDL. Timepoint: At baseline and after 8 weeks intervention. Method of measurement: Kit lab.;HDL. Timepoint: At baseline and after 8 weeks intervention. Method of measurement: Kit lab.	—

Measure

Time frame

Weight. Timepoint: at baseline and after 8 weeks intervention. Method of measurement: digital scale.;Waist circumstance. Timepoint: at baseline and after 8 weeks intervention. Method of measurement: measuring tape.;BMI. Timepoint: at baseline and after 8 weeks intervention. Method of measurement: Formula.;Blood pressure. Timepoint: at baseline and after 8 weeks intervention. Method of measurement: sphygmomonometer.;Fasting blood sugar. Timepoint: at baseline and after 8 weeks intervention. Method of measurement: lab kit.;Triglyceride. Timepoint: at baseline and after 8 weeks intervention. Method of measurement: lab kit.;Cholesterol. Timepoint: at baseline and after 8 weeks intervention. Method of measurement: lab kit.;LDL. Timepoint: At baseline and after 8 weeks intervention. Method of measurement: Kit lab.;HDL. Timepoint: At baseline and after 8 weeks intervention. Method of measurement: Kit lab.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKarim Parastouei

Bagheiat-allah University of Medical Sciences

parastoei@bmsu.ac.ir+98 21 8248 2341

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 1, 2026